Novel Therapeutic Approaches in Urothelial Carcinoma

Dear Colleagues,

Urothelial carcinoma (UC) is the tenth most commonly diagnosed cancer worldwide. Historically, five-year survival rates for patients with locally advanced diseases are about 36%, but drop to about 5% for patients with distant metastases. In recent years, diagnostic and therapeutic advances have led to lower mortality rates for patients with urothelial carcinoma (UC). The standard of care for advanced urothelial carcinoma remains platinum-based combination chemotherapy, followed by maintenance or sequential immunotherapy. However, the therapeutic landscape has recently been expanded with the Food and Drug Administration’s (FDA’s) approval of erdafitinib for tumors with a mutation or fusion, which activates fibroblast growth factor receptor (FGFR) 2 or FGFR3. In addition, two drug-conjugated antibodies, enfortumab vedotin (EV) and sacituzumab govitecan (SG), are indicated after progression to platinum-based chemotherapy and programmed cell death inhibitor 1 (PD1) or programmed cell death ligand 1 (PD-L1). Furthermore, the adoption of stereotactic body radiation therapy (SBRT) in the management of oligometastatic urothelial carcinoma can improve disease control.

There are several clinical trials ongoing with novel agents and drug combinations to further expand the therapeutic horizon of urothelial carcinoma.

The increasing number of long-term responders to new systemic treatments requires early identification and appropriate management of known and emerging toxicities.

The next step is the large-scale analysis of somatic and germline genomics, aimed at the development of therapies directed at tumor-specific, druggable genetic targets. In addition, the identification of specific biomarkers is crucial for developing personalized therapeutic strategies for urothelial carcinoma patients.

We invite you and your colleagues to submit original research articles or reviews focusing on:

• Genomic and molecular characterization of urothelial carcinoma;
• Identification of prognostic and predictive biomarkers;
• Future therapeutic perspectives;
• Management of emerging therapies.

Dr. Mimma Rizzo
Dr. Patrizia Giannatempo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• urothelial carcinoma
• immunotherapy
• targeted therapies
• antibody–drug conjugate
• biomarker
• radiotherapy